Inhibrx EBITDA Margin 2020-2022 | INBX

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Inhibrx (INBX) over the last 10 years. The current EBITDA margin for Inhibrx as of March 31, 2022 is .
Inhibrx EBITDA Margin Historical Data
2022-03-31 $0.01B $-0.08B -1050.00%
2021-12-31 $0.01B $-0.07B -925.00%
2021-09-30 $0.01B $-0.07B -900.00%
2021-06-30 $0.01B $-0.07B -590.91%
2021-03-31 $0.01B $-0.06B -453.85%
2020-12-31 $0.01B $-0.06B -438.46%
2020-06-30 $0.01B $-0.04B -840.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.452B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00